FDA Greenlights Streamlined Phase 2 Trial for Teverelix, Slashing Enrollment by Two-Thirds
MDCX sits 42% above its 52-week low of $0.25 on light trading volume (0.3× avg).
Summary
Medicus Pharma received FDA feedback and central IRB approval for an optimized Phase 2 study of Teverelix in acute urinary retention. The redesigned trial cuts enrollment from ~390 to ~126 patients, preserving the ability to generate decision-grade data while dramatically reducing costs. The FDA's seven recommendations are operational and do not require changes to the study's scientific rationale, primary endpoint, or planned interim analysis. This follows a period of severe financial distress—a going concern warning, Nasdaq delisting threat, and dilutive financings—making capital efficiency critical. The streamlined design could accelerate development and conserve cash, potentially extending the runway. Next steps include incorporating FDA feedback and initiating site-specific approvals before patient enrollment begins.
At the time of this announcement, MDCX was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.7M. The 52-week trading range was $0.25 to $3.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.